PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

Eligibility Criteria

• 1. Adult patients older than 40 years of age.
• 2. Diagnosis of Type 2 Diabetes Mellitus (insulin dependent or non-insulin dependent) for at least 5 years.
• 3. Diagnosis of Cardiovascular Disease (Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease, etc...) --OR--
• 1. Diabetic Retinopathy (proliferative or non-proliferative)
• 2. Diabetic Nephropathy (eGFR \<60 mL/min/1.73m2 and/or urine albumin/creatinine ratio ≥30 mg/g)
• 3. Diabetic Neuropathy
• 4. Elevated High-sensitivity C-reactive protein (hs-CRP) --AND--
• 5. Diagnosis of Hypertension for at least 6 months or more (treated or untreated)
• 6. Hypercholesterolemia (LDL-C \>100 mg/dL)
• 7. Obesity (Body Mass Index (BMI) ≥ 27 for men or ≥ 22 for women)
• 8. History of Smoking
• 4. Willingness to undergo HEMOTAG evaluation.
• 5. Willingness to undergo Standard of Care visits/assessments and NT-pro BNP lab evaluations.
• 6. Willingness to conduct at-home HEMOTAG evaluations at least three days per week within a 30-day time period after the completion of the Baseline Visit, after the 6 month visit and following discharge from any hospitalizations due to a cardiac events during the 12 month study period.
• 7. Willingness to receive and return shipping of the HEMOTAG KIT at each time point as required by the protocol
• 8. Able to give informed consent.
• 1. Terminal condition with life expectancy less than 12 months as determined by investigator.
• 2. Physical deformity in the chest area or lesion that may prevent proper HEMOTAG application or adjustment.
• 3. Illness/ Condition which may be aggravated or cause significant discomfort to the patient by the application of the HEMOTAG (skin issues, e.g. Intolerance to use of skin electrodes).
• 4. Participant enrolled in another interventional study (observational or registries are not excluded).
• 5. Prisoners and wards of the state.
• 6. Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator\'s assessment.
• 7. Participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (Exclude participants who necessitate the involvement of a legally authorized representative.)
• 8. Inability to provide informed consent (Must speak English).
• 9. Women who are pregnant or are planning to become pregnant during the study.
• 10. Women of childbearing potential who are unwilling or unable to comply with contraception measures.